Group 1 - The company announced that on November 10, 2025, the board received a written resignation from Zhang Changwei, who resigned from his position as a non-independent director due to work adjustments, while continuing to serve as the factory manager [1] - On the same day, the company held a staff representative meeting to elect Yin Yufeng as the employee representative director of the second board, with a term lasting until the end of the second board's term [1] - Zhang Changwei does not hold any direct shares in the company and will comply with relevant commitments after his resignation [1] Group 2 - Yin Yufeng has previously held positions within the company, including assistant manager and manager of the marketing department, as well as supervisor [1]

Core Viewpoint - The company reported that as of October 31, 2025, the number of shareholders will be 13,364 [1] Summary by Categories - Company Information - The company, Xiaofang Pharmaceutical (stock code: 603207), has communicated with investors regarding its shareholder count [1] - Shareholder Data - The projected number of shareholders by the end of October 2025 is 13,364 [1]

上海小方制药股份有限公司 2025 年第二次临时股东大会会议资料 2025 年 11 月 证券代码：603207 证券简称：小方制药 上海小方制药股份有限公司 2025 年第二次临时股东大会资料目录 | 2025 | 年第二次临时股东大会会议须知 | 3 | | --- | --- | --- | | 2025 | 年第二次临时股东大会会议议程 | 5 | | 2025 | 年第二次临时股东大会会议议案一 | 7 | | 2025 | 年第二次临时股东大会会议议案二 | 9 | | 2025 | 年第二次临时股东大会会议议案三 | 10 | 2 2025 年第二次临时股东大会会议须知 为了维护全体股东的合法权益，确保上海小方制药股份有限公司（以下简称"公 司"）股东大会的正常秩序和议事效率，保证大会的顺利进行，根据《中华人民共 和国公司法》《中华人民共和国证券法》《上市公司股东会规则》以及《上海小方 制药股份有限公司章程》（以下简称"《公司章程》"）《上海小方制药股份有限 公司股东大会议事规则》等相关规定，特制定本须知： 一、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作人 员将对出席会议者的 ...

Core Insights - Xiaofang Pharmaceutical, established in August 1993, is a well-known domestic external medicine company that focuses on R&D, production, and sales of external medicines, with certain technological barriers and brand advantages. The company is set to be listed on the Shanghai Stock Exchange on August 26, 2024 [1]. Financial Performance - For Q3 2025, Xiaofang Pharmaceutical reported a revenue of 397 million yuan, ranking 85th among 110 companies in the industry. The top company, Huadong Medicine, had a revenue of 32.664 billion yuan, while the industry average was 2.8 billion yuan [2]. - The net profit for the same period was 170 million yuan, placing the company 37th in the industry. The leading company, Hengrui Medicine, reported a net profit of 5.76 billion yuan, with the industry average at 299 million yuan [2]. Financial Ratios - As of Q3 2025, Xiaofang Pharmaceutical's debt-to-asset ratio was 19.39%, up from 11.91% the previous year, which is significantly lower than the industry average of 35.26%, indicating strong solvency [3]. - The gross profit margin for Q3 2025 was 66.74%, slightly up from 65.86% year-on-year, which is higher than the industry average of 57.17%, reflecting strong profitability [3]. Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.02% to 13,400, with an average holding of 4,073.08 circulating A-shares, which is an increase of 1.03% [5]. - Among the top ten circulating shareholders, Guangfa Multi-Dimensional Emerging Stock (003745) entered the list with 753,100 shares, while several funds exited the top ten [5]. Management Compensation - The chairman and general manager, Fang Zhiguang, received a salary of 1.2274 million yuan in 2024, unchanged from 2023 [4].

Group 1 - The core point of the article is that Xiaofang Pharmaceutical (603207.SH) reported its Q3 2025 results, highlighting significant institutional ownership and changes in public fund disclosures [1] - As of October 24, 2025, a total of 9 institutional investors hold shares in Xiaofang Pharmaceutical, amounting to 113 million shares, which represents 70.24% of the total share capital [1] - The institutional ownership decreased by 1.14 percentage points compared to the previous quarter [1] Group 2 - One new public fund was disclosed this period, namely the GF Multi-Dimensional Emerging Stock Fund [1] - A total of 121 public funds were not disclosed this period compared to the previous quarter, including several notable funds such as CITIC Securities Rotation Mixed A and CITIC Securities Selected Mixed A [1] Group 3 - In terms of foreign investment, one new foreign institution was disclosed, which is Yunjia Far East Co., Ltd [2] - The same foreign institution, Yunjia Far East Co., Ltd, was not disclosed in the previous quarter [2]

Core Viewpoint - Xiaofang Pharmaceutical (603207.SH) reported a year-on-year revenue increase of 8.17% for the first three quarters of 2025, reaching 397 million yuan, along with a net profit attributable to shareholders of 170 million yuan, reflecting a growth of 5.09% [1] Financial Performance - Total operating revenue for the first three quarters of 2025 was 397 million yuan, representing an 8.17% increase year-on-year [1] - Net profit attributable to the parent company's shareholders was 170 million yuan, showing a year-on-year growth of 5.09% [1] - Basic earnings per share stood at 1.06 yuan [1]

Group 1 - The core point of the article is that Xiaofang Pharmaceutical announced a board meeting to discuss the replacement of the auditing firm for the fiscal year 2025 [1] - For the fiscal year 2024, Xiaofang Pharmaceutical's revenue composition is 99.93% from pharmaceutical preparations and 0.07% from other businesses [1] - As of the report date, Xiaofang Pharmaceutical has a market capitalization of 5.2 billion yuan [1] Group 2 - The article highlights that Chinese innovative drugs have generated $80 billion in overseas licensing this year [1] - It discusses the current hot secondary market for biomedicine while noting that the primary market is facing challenges in fundraising [1]

上海小方制药股份有限公司 章 程 二○二五年十月 | 第一章 | 总则 | | --- | --- | | 第二章 | 经营宗旨和范围 2 | | 第三章 | 服份 | | 第一节 | 股份发行 . | | 第二节 | 股份增减和回购 | | 第三节 股份转让 . | | | 第四章 股东和股东会 | | | 第一节 | 股东的一般规定 | | 第二节 | 控股股东和实际控制人 . | | 第三节 | 股东会的一般规定 . | | 第四节 | 股东会的召集 . | | 第五节 | 股东会的提案与通知 | | 第六节 | 股东会的召开 . | | 第七节 股东会的表决和决议 | | | 第五章 | 董事会 | | 第一节 | 董事的一般规定 . | | 第二节 | 重事公 …………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………………… 27 | | 第三节 | 独立董事 | | 第四节 | 董事会专门委员会 . | | 第六章 | 高级管理人员 . | | 第七章 | ...

上海小方制药股份有限公司 股东会议事规则 二○二五年十月 | | | 上海小方制药股份有限公司 股东会议事规则 第一章 一般规定 公司董事会应当切实履行职责，认真、按时召集、组织股东会。公 司全体董事应当勤勉尽责，确保股东会的正常召开和依法行使职权。 第二章 股东会的职权 第三条 股东会由公司全体股东组成，是公司的权力机构｡ 股东会应当在《公司法》和公司章程规定的范围内行使职权｡ 1 第一条 为了进一步规范上海小方制药股份有限公司（以下简称"公司"） 股东会的议事方式和决策程序，保障公司股东会能够依法行使职权， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》等相关法律、法规以及《上海小方制药股份 有限公司章程》（以下简称"公司章程"）的规定，制定本议事规 则｡ 第二条 公司股东会的召集、提案、通知、召开等事项适用本议事规则。公 司应当严格按照法律、行政法规、公司章程及本议事规则的相关规 定召开股东会，保证股东能够依法行使权利。 第四条 股东会依法行使下列职权： （一） 选举和更换非由职工代表担任的董事，决定有关董事的 报酬事项； （二） 审议批准董事会的报告； （三） 审议 ...

上海小方制药股份有限公司 董事会议事规则 二○二五年十月 | | | 上海小方制药股份有限公司董事会议事规则 第一章 总 则 第二章 董事会的组成和下设机构 第三章 董事会的职权 1 第一条 为了进一步规范上海小方制药股份有限公司（以下简称"公司"） 董事会的议事方式和决策程序，促使董事和董事会有效地履行其职 责，提高董事会规范运作和科学决策水平，根据《中华人民共和国 公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》等相 关法律、法规以及《上海小方制药股份有限公司章程》（以下简称 "公司章程"）的规定，特制订本议事规则。 第二条 公司依法设立董事会。董事会是公司的经营决策机构，依据《公司 法》等相关法律、法规和公司章程的规定，经营和管理公司的法人 财产，对股东会负责。 第三条 公司董事会由 9 名董事组成。董事会设董事长 1 名。董事长由董事 会以全体董事的过半数选举产生。 第四条 董事会下设董事会办公室，处理董事会日常事务。董事会秘书兼任 董事会办公室负责人，保管董事会印章。 第五条 董事会应认真履行有关法律、法规和公司章程规定的职责，确保公 司遵守法律、法规和公司章程的规定，公平对待所有股东， ...